| Name | Title | Contact Details |
|---|
Segerstrom Center for the Arts is a leading performing arts complex located in Costa Mesa, California. Established in 1986 and renamed in 2011, it spans 14 acres and is recognized as Orange County’s largest non-profit arts organization. The Center features multiple venues, including Segerstrom Hall, Renée and Henry Segerstrom Concert Hall, Samueli Theater, and Judy Morr Theater, hosting a wide range of performances. The Center offers live performances that include Broadway shows, classical concerts, dance, and contemporary acts. It also provides venue rentals for private events and seminars, along with arts-based education programs through the Lawrence and Kristina Dodge Education Center. With a mission focused on artistic excellence and community engagement, the Center has welcomed over 20 million visitors and premiered over 60 world-class productions since its inception.
On September 27, 2022, FedNat Insurance Company ("FNIC") was placed into receivership by the Florida Office of Insurance Regulation (OIR). The Florida Department of Financial Services (DFS) now has authority over FNICs operations; including bank accounts. A copy of the Liquidation Order for FedNat Insurance Company is available on the Departments website, www.myfloridacfo.com/division/receiver. The Department is currently gathering claim files and claim data to forward the information to applicable GAs. As a result, there may be a slight delay in claim processing during this transitional period. The Departments website, www.myfloridacfo.com/division/receiver, will be updated as appropriate regarding the claim transfer process. A Guaranty Association ("GA") is a nonprofit corporation statutorily created to provide a mechanism for the payment of policy related loss claims and unearned premium when an insurance company is liquidated. For more information, you can find specific information about your states Guaranty Association at: Alabama Insurance Guaranty Association - 205-823-4042 Florida Insurance Guaranty Association - https://figafacts.com/ Georgia Insurers Insolvency Pool – https://www.gaiga.org Louisiana Insurance Guaranty Association - https://www.laiga.org/ Mississippi Insurance Guaranty Association - https://ms-miga.com/ South Carolina Property and Casualty Insurance Guaranty Association - http://www.scguaranty.com/ Texas Property and Casualty Insurance Guaranty Association - http://www.tpciga.org/ For information on a bounced check or the time it will take to receive a replacement check contact the Department at 1-800-882-3054 or online at http://myfloridacf
Tanner is the intermountain area's premier professional services firm. At Tanner, our personal approach guarantees that you will work closely and consistently with partners and with team members who understand your business and personal objectives.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.